Special Issue "Recent Advancements in the Influenza and other Respiratory Virus Research"

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".

Deadline for manuscript submissions: closed (28 February 2021).

Special Issue Editors

Dr. Binod Kumar
E-Mail Website
Guest Editor
Loyola University Chicago, Illinois, USA
Interests: Viral entry and pathogenesis; epidemiology; antiviral strategies; innate immunity against viruses
Dr. Kumari Asha
E-Mail
Guest Editor
Rosalind Franklin University of Medicine and Science, North Chicago, USA
Interests: Influenza virus; Viral pathogenesis, innate immunity; viral epidemiology
Dr. Melvin Sanicas
E-Mail
Guest Editor
Takeda Pharmaceuticals International, Zurich, Switzerland
Interests: Viral epidemiology; vaccines; antiviral research
Dr. Clement Meseko
E-Mail
Guest Editor
National Veterinary Research Institute, Vom, Nigeria
Interests: Viral epidemiology; Vaccines; Avian influenza

Special Issue Information

Dear Colleagues,

Respiratory viral infections are one of the leading causes of annual morbidity and mortality imposing a significant disease burden worldwide. The severity of the respiratory illness may vary from the milder and asymptomatic respiratory tract infection to severe wheezing, bronchiolitis, or pneumonia. Respiratory viruses such as the influenza viruses, parainfluenza viruses, respiratory syncytial virus (RSV) or the respiratory adenoviruses have been the major concerns affecting not only infants and children but also the young by imposing a large and intermittent burden on the health care infrastructure. These viruses often share tropism with cells of the respiratory tract and show rapid transmission through air/aerosols or via direct-indirect contact with infected persons imposing significant disease burden than any other disease.

Influenza viruses, among all these, continuously acquire point mutations while circulating in wide range of hosts, ranging from wild aquatic birds to mammals, including humans. The wide range of host very often provides opportunities of genetic re-assortment, leading to the emergence of zoonotic strains that may cause pandemics leading to a severe impact on human life. The 2009-influenza pandemic is the recent example of the ability of a virus to undergo genetic re-assortment and spread with an unprecedented speed and become global health concern. The other respiratory viruses also impose severe threat to life of infants, immunocompromised adults and other high risk groups that closely work with infected patients. Vaccination is still the best strategy for management of these respiratory viruses, although there are some major challenges due to the inadequate response during immunization of young infants and the circulation of the antigenically distinct viral strains. It is very important to timely diagnose these viral infections as they often have overlapping clinical presentations and cause both upper respiratory tract infection (URTI) and LRTI, and often misdiagnosed by attending physicians unless a laboratory diagnosis is done for the causative agent.

A continuous surveillance must be implemented across the globe to monitor the changing epidemiology and pathogenesis of these respiratory viruses. We need more advanced understanding of the viral pathobiology, development of better and effective vaccines and antiviral strategies to manage such infections.

In this special issue, we aim to assemble a collection of original research and review articles to provide a comprehensive view on the recent research advancements made towards the changing epidemiology, the evolutionary patterns, pathogenesis mechanisms, diagnostics, and management of these major respiratory viral infections.

The potential topics include but are not limited to the following:

  • Recent reports of emerging and reemerging respiratory viral infections
  • Changing patterns in the epidemiology of respiratory viruses
  • Mechanisms of viral pathogenesis
  • Evolutionary and transmission patterns of respiratory viruses
  • Advancements made in the vaccine development and antiviral strategies
  • Recent developments in the diagnostics of respiratory viruses

Dr. Binod Kumar
Dr. Kumari Asha
Dr. Melvin Sanicas
Dr. Clement Meseko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Influenza virus
  • RSV, Adenovirus, parainfluenza virus
  • Epidemiology
  • vaccines
  • antiviral strategy
  • viral diagnosis
  • viral evolution

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

Open AccessFeature PaperArticle
Inactivation of Human Coronavirus by FATHHOME’s Dry Sanitizer Device: Rapid and Eco-Friendly Ozone-Based Disinfection of SARS-CoV-2
Pathogens 2021, 10(3), 339; https://doi.org/10.3390/pathogens10030339 - 14 Mar 2021
Viewed by 666
Abstract
The pandemic of SARS-CoV-2/COVID-19 was reported in December 2019 in Wuhan, China. Pertaining to its high transmissibility and wide host adaptability, this unique human coronavirus spread across the planet inflicting 115 million people and causing 2.5 million deaths (as of March 3rd, 2021). [...] Read more.
The pandemic of SARS-CoV-2/COVID-19 was reported in December 2019 in Wuhan, China. Pertaining to its high transmissibility and wide host adaptability, this unique human coronavirus spread across the planet inflicting 115 million people and causing 2.5 million deaths (as of March 3rd, 2021). Limited or negligible pre-existing immunity to multiple SARS-CoV-2 variants has resulted in severe morbidity and mortality worldwide, as well as a record-breaking surge in the use of medical-surgical supplies and personal protective equipment. In response to the global need for effective sterilization techniques, this study evaluated the virucidal efficacy of FATHHOME’s self-contained, ozone-based dry-sanitizing device, by dose and time response assessment. We tested inactivation of human coronavirus, HCoV-OC43, a close genetic model of SARS-CoV-2, on porous (N95 filtering facepiece respirator/FFR) and nonporous (glass) surfaces. We started our assays with 20 ppm-10 min ozone exposure, and effectively reduced 99.8% and 99.9% of virus from glass and N95 FFR surfaces, respectively. Importantly, the virus was completely inactivated, below the detection limit (over 6-log10 reduction) with 25 ppm-15 min ozone exposure on both tested surfaces. As expected, a higher ozone exposure (50 ppm-10 min) resulted in faster inactivation of HCoV-OC43 with 100% inactivation from both the surfaces, with no residual ozone present after completion of the 5-min post exposure recapture cycle and no measurable increase in ambient ozone levels. These results confirmed that FATHHOME’s device is suitable for rapid decontamination of SARS-CoV-2- from worn items, frequently touched items, and PPE including N95 FFRs, face shields, and other personal items. Full article
Show Figures

Figure 1

Other

Jump to: Research

Open AccessCase Report
From Upper Respiratory Symptoms to Hemophagocytic Lymphohistiocytosis: Case Report of a Human Adenovirus Infection in Haploidentical Hematopoietic Stem Cell Transplant Recipient
Pathogens 2021, 10(3), 340; https://doi.org/10.3390/pathogens10030340 - 15 Mar 2021
Viewed by 274
Abstract
Human adenovirus infection is rare in adult population, except for in immunocompromised individuals. Recipients of allogenic haploidentical hematopoietic stem cell transplantation are reported at high risk for human adenovirus, which is often lethal when it evolves into the disseminated form. Despite existent guidelines, [...] Read more.
Human adenovirus infection is rare in adult population, except for in immunocompromised individuals. Recipients of allogenic haploidentical hematopoietic stem cell transplantation are reported at high risk for human adenovirus, which is often lethal when it evolves into the disseminated form. Despite existent guidelines, prevention, early diagnosis, and therapeutics remain challenging. Here, we report the case of a fatal evolution of human adenovirus respiratory infection and discuss the actual recommendations to prevent recurrence of this major issue. Full article
Show Figures

Figure 1

Back to TopTop